Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06707025

The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma

The investigators found an inverse relationship between CD24 and MiR-122 levels. Then the investigators found that CD24 that goes up with MiR-122 down makes macrophages unable to engulf the tumor cells. All this in mice. the investigators are interested in confirming this result in humans. Details of the preliminary results are attached to the submission of the research documents. the investigators will compare Cholangiocarcinoma tumors with other solid tumors, including liver tissue. The need to deepen understanding the investigators will also make a comparison between cancerous tissue and "normal" tissue adjacent to the tumor.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hdassah Hospital

Jerusalem, Israel, 9112001

About this study

The investigators will collect samples from the tissue bank. All materials will be kept in refrigerators at minus 80, except for the sections of the paraffin blocks at room temperature. The source of some of the biological samples and the information accompanying them in this study is Midgem - the Israeli repository for biological samples for research. Midgem is a non-profit association that operates within the Ministry of Health as an infrastructure for the promotion of bioresearch - Medical and industrial in Israel. The donors to Midgem are patients with malignant diseases, Non-malignant diseases as well as healthy volunteers. In Midgem, residues are collected from tissues already removed during surgery/taking a biopsy and/or samples from blood/saliva/urine/other body fluids donations and the accompanying medical information required for use in legally approved studies.There is no risk to the donors as a result of the donation of the samples and information and their use, since the donation is transferred to Midgem only after it has been ascertained beyond any doubt that the ability of the diagnosis and/or treatment of the donors will not be harmed. All the information transferred to the researchers is coded, in such a way that the investigators do not allow the identification of the donors' details. Since the donors to Midgem have signed a consent form for the collection and storage of samples and information for use in any legally approved study, the investigators request an exemption from signing a dedicated informed consent form for this study. The samples and information transferred to this study are donated in accordance with what is detailed in the inclusion criteria for the experiment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Donors with cholangiocarcinoma samples

Exclusion criteria

  • Donors who do not have cholangiocarcinoma samples

Treatment and study plan

Primary outcomes

  1. the investigators will analyze ductular reaction and cancer stem cells markers including CD24, CD44

    Time frame: All along the study, from the first recruitment to the last recruitment. average of 1 year

    the investigators will perform the analysis on tissue samples of cholangiocarcinoma and non tumor controls, using immunohistochemistry and RT-PCR

Sponsors and collaborators

Lead sponsor

Hadassah Medical Organization

Other

Registry information

Acronym: CD24CCA

Important dates

Study start
2023
Primary completion
2024
Study completion
2026
First posted
Nov 27, 2024
Registry last updated
Mar 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.